NASDAQ: VTYXVentyx Biosciences Inc Stock
$4.06-0.18 (-4.25%)
Updated Apr 25, 2024
VTYX Price
$4.06
Fair Value Price
$0.67
Market Cap
$240.56M
52 Week Low
$1.87
52 Week High
$40.58
P/E
-1.23x
P/B
0.99x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$192.96M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.14
Operating Cash Flow
-$167M
Beta
1.33
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A
VTYX Overview
Ventyx Biosciences Incorporated is a biopharmaceutical company developing small molecule products for inflammatory diseases and autoimmune disorders. The company's lead product candidates are VTX958, a tyrosine kinase type 2 inhibitor in phase I clinical trials for the treatment of immune-mediated diseases, and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases. The company is also developing CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease and other neurodegenerative disorders. Ventyx was incorporated in 2018 and is headquartered in Encinitas, CA.
Zen Score
–
Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VTYX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VTYX ($4.06) is overvalued by 508.31% relative to our estimate of its Fair Value price of $0.67 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VTYX ($4.06) is not significantly undervalued (508.31%) relative to our estimate of its Fair Value price of $0.67 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VTYX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VTYX due diligence checks available for Premium users.
Be the first to know about important VTYX news, forecast changes, insider trades & much more!
VTYX News
Valuation
VTYX fair value
Fair Value of VTYX stock based on Discounted Cash Flow (DCF)
Price
$4.06
Fair Value
$0.67
Overvalued by
508.31%
VTYX ($4.06) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VTYX ($4.06) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VTYX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VTYX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.23x
Industry
15.41x
Market
40.97x
VTYX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.99x
Industry
5.8x
VTYX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VTYX's financial health
Profit margin
Revenue
$0.0
Net Income
-$46.8M
Profit Margin
0%
VTYX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$277.7M
Liabilities
$33.8M
Debt to equity
0.14
VTYX's short-term assets ($264.35M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VTYX's short-term assets ($264.35M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VTYX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$51.7M
Investing
$46.1M
Financing
$585.0k
VTYX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VTYX vs Biotech Stocks
Ventyx Biosciences Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.